Lupin Limited has informed the Exchange about press release dated 05-Apr-2022 titled Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region.
Press Release Apr 05 2022
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Press Release Mar 24 2022
- Press Release Mar 11 2022
- Press Release Mar 10 2022
- Press Release Mar 09 2022
- Press Release Mar 07 2022
Later from Lupin
- Press Release Apr 07 2022
- Press Release Apr 14 2022
- Press Release Apr 18 2022
- Press Release Apr 27 2022
- Press Release Apr 29 2022
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin